Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

218

Full text

163

Free full text

132

Publication Types

Journal Article

210

Research Support, Non-U.S. Gov't

Review

Multicenter Study

Clinical Trial, Phase II

Randomized Controlled Trial

Research Support, N.I.H., Extramural

Case Reports

Clinical Trial, Phase III

Observational Study

Systematic Review

Meta-Analysis

Comparative Study

Clinical Trial, Phase I

Clinical Trial

Letter

Clinical Trial Protocol

Equivalence Trial

Research Support, N.I.H., Intramural

Research Support, U.S. Gov't, Non-P.H.S.

Validation Study

Research Support, U.S. Gov't, P.H.S.

Interview

Editorial

Publication Year

From

Quick links

Individual year

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for

""Antineoplastic Agents, Immunological""[mesh_terms]

223 Results

Searching titles within these results

ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.

Yun Shi, Min Shen, Xuqin Zheng, Yang Chen, RuiLing Zhao, Yong Gu, Tao Yang

The Journal of clinical endocrinology and metabolism 2021;105(12):dgaa553

Full Text

Abstract

Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis.

Pei-Mei Zou, Hang Li, Jian-Fang Cai, Zhen-Jie Chen, Chao Li, Xue-Wang Li

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 2019;33(1):9-19

Full Text

Abstract

Management of Immune-Related Endocrinopathies in Anticancer Treatment with Checkpoint Inhibitors.

R Lakomý, A Poprach, T Kazda

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2020;33(1):15-19

Full Text

Abstract

CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.

Lauren A Dalvin, Carol L Shields, Marlana Orloff, Takami Sato, Jerry A Shields

Retina (Philadelphia, Pa.) 2018;38(6):1063-1078

Full Text

Abstract

Renal Toxicity of Cancer Immunother apy.

T Büchler

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2020;33(1):29-31

Full Text

Abstract

Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.

Li Jia, Ying Wang, Jinhui He, Mi Chen

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025;35(9):101978

Free Full Text

Abstract

Altered cancer metabolism in mechanisms of immunotherapy resistance.

Rishab Ramapriyan, Mauricio S Caetano, Hampartsoum B Barsoumian, Ana Carolina P Mafra, Erika Pereira Zambalde, Hari Menon, Efrosini Tsouko, James W Welsh, Maria Angelica Cortez

Pharmacology & therapeutics 2020;195():162-171

Full Text

Abstract

Immune-related cutaneous adverse events due to checkpoint inhibitors.

Evelyn Wang, Lukas Kraehenbuehl, Kwami Ketosugbo, Jeffrey A Kern, Mario E Lacouture, Donald Y M Leung

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021;126(6):613-622

Free Full Text

Abstract

Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.

Alexi Vasbinder, Anis Ismail, Joe-Elie Salem, Salim S Hayek

Current cardiology reports 2023;25(9):959-967

Free Full Text

Abstract

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.

Charlotte Fenioux, Baptiste Abbar, Samia Boussouar, Marie Bretagne, John R Power, Javid J Moslehi, Paul Gougis, Damien Amelin, Agnès Dechartres, Lorenz H Lehmann, Pierre-Yves Courand, Jennifer Cautela, Joachim Alexandre, Adrien Procureur, Antoine Rozes, Sarah Leonard-Louis, Juan Qin, Rémi Cheynier, Benedicte Charmeteau-De Muylder, Alban Redheuil, Florence Tubach, Jacques Cadranel, Audrey Milon, Stéphane Ederhy, Thomas Similowski, Douglas B Johnson, Ian Pizzo, Toniemarie Catalan, Olivier Benveniste, Salim S Hayek, Yves Allenbach, Michelle Rosenzwajg, Charles Dolladille, Joe-Elie Salem

Nature medicine 2023;29(12):3100-3110

Full Text

Abstract

Optimizing immunotherapy for colorectal cancer.

Karuna Ganesh

Nature reviews. Gastroenterology & hepatology 2022;19(2):93-94

Free Full Text

Abstract

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.

Yoon-Koo Kang, Satoshi Morita, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Hiroki Sameshima, Li-Tzong Chen, Narikazu Boku

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2022;25(1):207-217

Free Full Text

Abstract

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.

Natalia L Gonzalez, Araya Puwanant, Angela Lu, Stanley M Marks, Saša A Živković

Neuromuscular disorders : NMD 2018;27(3):266-268

Full Text

Abstract

New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.

Lukas Delasos, Christopher Bazewicz, Aleksandra Sliwinska, Nerea Lopetegui Lia, James Vredenburgh

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021;27(3):716-721

Full Text

Abstract

Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.

Enrica Antonia Martino, Antonella Bruzzese, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Ernesto Vigna, Fortunato Morabito, Massimo Gentile, Noemi Puccio, Antonino Neri

European journal of haematology 2025;114(3):386-399

Free Full Text

Abstract

Results: 1 – 15 / 223

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Antineoplastic Agents, Immunological""[mesh_terms]

ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management.

Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis.

Management of Immune-Related Endocrinopathies in Anticancer Treatment with Checkpoint Inhibitors.

CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.

Renal Toxicity of Cancer Immunother apy.

Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets.

Altered cancer metabolism in mechanisms of immunotherapy resistance.

Immune-related cutaneous adverse events due to checkpoint inhibitors.

Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.

Optimizing immunotherapy for colorectal cancer.

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.

New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.

Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.

Results for

""Antineoplastic Agents, Immunological""[mesh_terms]